Creative Commons Attribution-Share Alike 4.0 International license.
Treatment with anti-SARS-CoV-2 monoclonal antibodies should be considered for patients with mild to moderate COVID-19 who are hospitalized for a reason other than COVID-19 if they otherwise meet the FDA Emergency Use Authorization (EUA) criteria for outpatient treatment.
The risk for progression to severe COVID-19 in high-risk patients is substantially greater for those who are not vaccinated or those who are vaccinated but not expected to mount an adequate immune response to the vaccine due to an underlying immunocompromising condition. At this time, the Panel’s anti-SARS-CoV-2 monoclonal antibodies recommendations are for the treatment of nonhospitalized patients with mild to moderate COVID-19 who are at high risk of progressing to severe disease.
- Click on the PDF link below to access this section.
- Return to this page. Click “Next” below access the next section.
- The last section provides a link to the quiz, registration, payment, and certificate.